Drug Profile
12 D7G
Alternative Names: 12-D7G; 12D7; Anti-NY-ESO-1 monoclonal antibody - XBiotech; CTA-001Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator CT Atlantic AG
- Developer CT Atlantic AG; Ludwig Institute for Cancer Research; University of Zurich
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CTAG1B protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer